You never know when an allergic reaction might occur - and in who. But we do know that adrenaline pens are hard to source, and that often they have very short shelf lives.

That’s why we’re so excited that we can offer an all-in-one service, giving you guaranteed long-life adrenaline pens, automatically replenished before they expire, and easily stored in our accessible wall-mounted Kitts , for use in emergencies. We also replenish any pens that are used at no extra cost if you report an incident on our Portal.

Many organisations face issues with training as it’s often costly (in both time and money) to organise, and often staff don’t even turn up to do it.

That’s why we include unlimited CPD-accredited Anaphylaxis Kitt training right into the subscription package, with 30 minutes of instantly accessible, easily digestible videos on allergy and anaphylaxis followed by quiz questions. Also, through our Kitt Portal, you can track who’s completed the training (and who hasn’t), making it easy to audit.

Overall, organisations from industries across the UK are calling us a ‘no-brainer’ - find out why by enquiring today.

Our Anaphylaxis Kitt service is charged per Kitt per year, on 5-year agreements.

For qualifying businesses, please get in touch to arrange a meeting with a member of our team so we can discuss a package that suits your needs.

This will include:

• Wall-mounted Kitts with four keys and emergency breakable key box

• One trainer adrenaline pen with each Kitt

• Adrenaline pens, automatically replenished before expiry or if used and reported to us

• Unlimited staff access to our online CPD-accredited training course

• Access to our online portal for Kitt check-up reminders, incident report forms, and medication management.

Not all anaphylaxis safety solutions are the same, and when you look at what's genuinely included, Kitt consistently represents better value than the alternatives.

Many providers charge separately for equipment, training, and ongoing adrenaline replenishment. With Kitt, everything is bundled into a single subscription:

• 4 adrenaline auto-injectors, each retailing at approximately £80 - £100 through standard pharmacy channels

• Unlimited CPD-accredited staff training for your whole team, delivered online - Standalone CPD-accredited training typically costs £10–£20 per person per cohort, with no unlimited access, whereas Kitt includes unlimited repeats for all staff.

• A secure, wall-mounted Kitt unit, designed and manufactured in the UK from recycled materials

• Year-round replenishment guarantees, covering pens that expire or are used in an emergency, with no unexpected replacement costs

Priced independently, these components add up quickly. Kitt brings them together in one predictable annual subscription, removing the administrative burden of managing multiple suppliers, tracking expiry dates, and arranging separate training programmes.

For schools and venues working within fixed budgets, that simplicity has real financial value, not just in pounds saved, but in staff time and peace of mind.

We are a small, independent London-based business with our Kitts made out of recycled plastic in the UK. Our pricing reflects the true cost of delivering a complete, reliable service - and we believe that when compared fairly against the alternatives, it speaks for itself.

Our Anaphylaxis Kitt service can only be purchased in the UK by registered schools and qualifying businesses with an occupational health scheme (OHS) available.

By UK law, an organisation must have OH to purchase adrenaline pens. This could be an internal company OH physician/nurse, or a third-party provider you have available to the business (e.g. Health Assured). If you're not sure, think about who you would report an employee's mental or physical issue to...

We've found that due to a lack of OHS available, businesses such as aesthetics clinics, independent nurseries and small groups such as scouts unfortunately don't currently qualify.

This is not our decision, but rather the current UK legislation (Schedule 17 of The Human Medicines Regulations 2012).